Dr. Reddy's Books INR 240-Crore Semaglutide Charge
Dr. Reddy's booked an INR 240-crore provision after an API quality failure forced a halt to semaglutide commercial supplies, reducing Q1 EBITDA margin to 12.5% on a consolidated basis against an adjus
Dr. Reddy's Halts Semaglutide Sales, Margin Hits 12.5%
NEW YORK, August 12 —
Dr. Reddy's Laboratories Limited (RDY) booked an INR 240-crore provision, halted semaglutide commercial supplies after an API quality failure, and posted a 12.5% EBITDA margin. CEO Erez Israeli put 80-to-90% odds on resolving the underlying chemistry and projected 6 to 7 million pens shipped by March. September test results will determine whether the second-half recovery thesis survives.
- Q1 revenue INR 8,071 crores ($853M), down 5.6% year over year; EBITDA margin 12.5% on consolidated basis.
- Semaglutide provision: INR 240 crores; reported gross margin 46.5% versus 49.4% excluding the provision.
- North America revenue fell 41% year over year to $236M as lenalidomide exclusivity revenue collapsed.
The 80% Problem
The semaglutide stumble emerged after 180,000 pens had already shipped. Dr. Reddy's, a Hyderabad-based manufacturer of generic drugs, active pharmaceutical ingredients, and biosimilars, halted commercial supplies, booking the INR 240-crore provision for inventory and associated costs. Strip it out and EBITDA margin rises to 15.4%, gross margin to 49.4%. But the provision is sunk. What management is now selling investors is the recovery: 6 to 7 million pens between November 2026 and March 2027, replacing the 3 to 4 million units already missed. Israeli's own 80-to-90% odds estimate implies a 10-to-20% scenario in which that provision is just the opening bid.
India and Emerging Markets Carry the Quarter
India and emerging markets gave Dr. Reddy's something to stand on. India revenue grew 17% year over year to INR 1,780 crores; emerging markets rose 31% to INR 1,833 crores, with 43 new products launched across countries. North America, generating $236 million or 27% of Q1 revenue, fell 41% as lenalidomide exclusivity faded, though management said the underlying base delivered double-digit growth. Six new U.S. products launched in the quarter, including bosutinib in the 400-milligram strength, a first-to-market generic carrying 180 days of exclusivity. The base is growing; the question is whether semaglutide can fill what lenalidomide left, a variable investors can size now with the DCF calculator before September.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| RDY | $10.3B | 19.0x | -12.7% |
| WIT | $19.4B | 13.1x | -27.8% |
| IBN | $107.1B | 16.1x | -8.5% |
| HDB | $119.3B | 16.3x | -37.1% |
| INFY | $50.0B | 14.5x | -23.1% |
September Is the Number
The next disclosure that matters is not a quarterly report; it is the API test result, expected in the third week of September 2026. A clean read opens management's declared path: commercial supplies in November, 6 to 7 million pens by March. A failed test leaves Dr. Reddy's in fiscal H2 without a catalyst, with the PSAI segment already contracting 5% year over year and a seven-observation FDA Form 483 from June's Bachupally biologics inspection awaiting resolution. Management reaffirmed double-digit base growth, but that framing depends on a chemistry outcome six weeks away. Run the free Dr. Reddy's Laboratories Limited deep-dive → to track the September result.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Dr. Reddy's halt semaglutide sales?
Dr. Reddy's halted commercial semaglutide supplies after an API quality failure was identified. The company booked an INR 240-crore provision covering inventory and associated costs. By that point, 180,000 pens had already shipped before the halt was implemented.
What was Dr. Reddy's Q1 EBITDA margin?
Dr. Reddy's reported a consolidated Q1 EBITDA margin of 12.5%. Excluding the INR 240-crore semaglutide provision, the adjusted EBITDA margin would have been 15.4% and gross margin 49.4%, versus the reported 46.5%.
How much did Dr. Reddy's North America revenue fall?
North America revenue declined 41% year over year to $236 million, representing 27% of Q1 revenue. The decline was driven primarily by the collapse of lenalidomide exclusivity revenue, though management said the underlying base delivered double-digit growth.
When will Dr. Reddy's resume semaglutide shipments?
Management projected shipments of 6 to 7 million pens between November 2026 and March 2027. CEO Erez Israeli assigned 80-to-90% odds to resolving the underlying chemistry issue, with the critical API test result expected in the third week of September 2026.
How did India and emerging markets perform for Dr. Reddy's?
India revenue grew 17% year over year to INR 1,780 crores, while emerging markets rose 31% to INR 1,833 crores. Dr. Reddy's launched 43 new products across countries in the emerging markets segment during the quarter.
Dr. Reddy's Laboratories reported a 5.6% revenue decline and an EBITDA margin collapse to 12.5% in its fiscal first quarter after a semaglutide API quality problem forced the company to halt commercial supplies — booking an INR 240-crore write-off — while CEO Erez Israeli simultaneously projected shipping 6 to 7 million semaglutide pens between November and March. The catch: Israeli himself rates the probability of resolving the underlying chemistry problem at only 80 to 90 percent.